Abstracts tagged "B cells"

Abstract Number: 2071 • 2012 ACR/ARHP Annual Meeting
The Potent, Highly Selective and Orally Bioavailable Spleen Tyrosine Kinase Inhibitor GSK143 Demonstrates Efficacy in B Cell Receptor and Fc Receptor Signalling in Models of Inflammatory and Autoimmune Disease
Marion C. Dickson¹, Nicholas Smithers², Huw Lewis¹, Cesar Ramirez-Molina¹, Scott McCleary¹, Mike Barker¹ and John Liddle¹, ¹Immuno Inflammation, GSK, Stevenage, United Kingdom, ²Immuno Inflammation, GlaxoSmithKline, Stevenage, United Kingdom
Background/Purpose: Spleen tyrosine kinase (Syk), a 72 KDa cytosolic non-receptor tyrosine kinase is a key mediator of B cell receptor (BCR) and Fc receptor (FcR)…
Abstract Number: 1749 • 2012 ACR/ARHP Annual Meeting
Targeting of CD22 by Epratuzumab Potentially Raises the Threshold of B Cell Receptor Activation
N. Sieger¹, S.J. Fleischer¹, K. Reiter¹, H.E. Mei¹, A. Shock², G. Burmester¹, C. Daridon³ and Thomas Dorner¹, ¹Department of Medicine/Rheumatology and Clinical Immunology and German Rheumatism Research Centre Berlin (DRFZ), Charité University Medicine Berlin, Berlin, Germany, ²UCB Pharma, Slough, United Kingdom, ³Department of Medicine/Rheumatology and Clinical Immunology, Charité University Medicine / German Rheumatism Research Centre Berlin (DRFZ), Berlin, Germany
Background/Purpose: CD22, a member of the sialic acid-binding immunoglobulin-like lectins (Siglec) family, is exclusively expressed on B cells at mature stage and is lost upon…
Abstract Number: 652 • 2012 ACR/ARHP Annual Meeting
Serum Rituximab Levels and Efficiency of B-Cell Depletion: Differences Between Patients with Systemic Lupus Erythematosus and Rheumatoid Arthritis
Venkat Reddy¹, Sara Croca², Delia Gerona³, Inmaculada De La Torre Ortega³, David A. Isenberg⁴, Maria Leandro² and Geraldine Cambridge⁵, ¹Rheumatology, University College London, London, United Kingdom, ²Centre for Rheumatology Research, Division of Medicine, University College London, London, United Kingdom, ³Rheumatology, Gregorio Marañón Hospital, Madrid, Spain, ⁴Centre for Rheumatology Research, Rayne Building, 4th Floor, Centre for Rheumatology, Department of Medicine, University College London, London, United Kingdom, ⁵Centre for Rheumatology, Department of Medicine, University College London, London, United Kingdom
Background/Purpose: Variability in rituximab-induced B-cell depletion (BCD) occurs in a significant number of patients with Systemic Lupus Erythematosus (SLE) and to a lesser extent in…
Abstract Number: 1783 • 2012 ACR/ARHP Annual Meeting
TNFα Influences RasGRP1 and RasGRP3 Expression Levels in PBMC, B and T Cells
Marie-Laure Potier¹, Martine Hiron¹, Clément Guillou¹, Céline Derambure², Olivier Boyer³, Xavier Le Loët⁴, Olivier Vittecoq⁵ and Thierry Lequerré⁶, ¹Inserm 905 & Institute for Biomedical Research, University of Rouen, Rouen, France, ²Inserm 905 & Institute for Biomedical Research, University of Rouen, Rouen, France, Rouen, France, ³Immunology, Inserm 905, Institute for Biomedical research, University of Rouen, Rouen, France, ⁴Rheumatology Department, Department of Rheumatology, Rouen University Hospital & Inserm 905, Institute for Biomedical Research, University of Rouen, Rouen Cedex, France, ⁵Rheumatology, Department of Rheumatology, Rouen University Hospital & Inserm 905, Institute for Biomedical Research, University of Rouen, Rouen Cedex, France, ⁶Rheumatology Department & Inserm 905, Department of Rheumatology, Rouen University Hospital & Inserm 905, Institute for Biomedical Research, University of Rouen, Rouen Cedex, France
Background/Purpose: Rheumatoid arthritis (RA) is the most common inflammatory arthritis. B and T lymphocytes play a central role in the pathophysiology of RA. RasGRP is…
Abstract Number: 1751 • 2012 ACR/ARHP Annual Meeting
Effect of Repeated Infusions of Rituximab in Patients with Primary Sjögren’s Syndrome
Maria Perez-Ferro¹, Sheila Recuero², Fredeswinda I. Romero¹, Cristina Serrano³, Maria J. Rodriguez-Nieto⁴, Julio Gomez-Seco², Teresa Presa², Javier R. Godo², Gabriel Herrero-Beaumont⁵ and Olga Sanchez-Pernaute², ¹Section for Autoimmune Diseases, Rheumatology, Jiménez Díaz Foundation University Hospital, Madrid, Spain, ²Jimenez Díaz Foundation University Hospital, Madrid, Spain, ³Immunology, Jiménez Díaz Foundation University Hospital, Madrid, Spain, ⁴Section for Autoimmune Diseases. Pneumology, Jimenez Díaz Foundation University Hospital, Madrid, Spain, ⁵Bone and Joint Research Unit, IIS-Fundación Jiménez Díaz, Madrid, Spain
Background/Purpose: To assess the safety and efficacy of repeated infusions of rituximab (RTX) in patients with primary Sjögren syndrome (PSS). Methods: Patients with PSS were…
Abstract Number: 616 • 2012 ACR/ARHP Annual Meeting
Bioavailability, Pharmacokinetics, and Safety of Belimumab Administered Subcutaneously in Healthy Subjects
Wendy Cai¹, Cecil Chen¹, Z. John Zhong¹, William W. Freimuth¹, William Lewis² and David Subich³, ¹Human Genome Sciences, Inc., Rockville, MD, ²Covance Clinical Research Unit, Inc., Dallas, TX, ³Covance Clinical Research Unit, Inc., Daytona Beach, FL
Background/Purpose: Belimumab is a recombinant, human Ig-G1λ monoclonal antibody that binds and antagonizes the biological activity of soluble B-lymphocyte stimulator protein, a member of the…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].